Convatec, a global leader in medical products and technologies, has announced plans to invest more than $1 billion over the next decade to accelerate its research and development (R&D) ambitions worldwide.
This global, multi-year planned investment marks a significant milestone in Convatec’s mission to deliver breakthrough healthcare solutions and underlines its long-standing commitment to both the United States and the United Kingdom as cornerstones of its global growth strategy.
As part of this plan, Convatec will invest $600m over the next ten years in R&D in the US, underlining the company’s long-term commitment to its most significant market globally. The plans include a significant expansion of its world-class R&D facilities in Boston, United States, by end 2025 – increasing capacity by 50% and further enhancing lab, testing and collaboration space.
In the United Kingdom, Convatec plans to invest £500 million (approximately $650 million), including a new state-of-the-art R&D hub in Manchester, set to open in 2027. The new facility will be one of the largest in Convatec’s global network of Technology & Innovation Centres, with the potential to provide common or shared R&D capabilities and competences across all four of Convatec’s categories: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. It will also house cutting-edge analytical R&D capabilities, regulatory functions, and digital health innovation, positioning Convatec at the forefront of medical technology development.
Date: 5 October